NASDAQ:FULC
Fulcrum Therapeutics, Inc. Stock News
$7.75
+0.1000 (+1.31%)
At Close: May 03, 2024
– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with FSHD clinical endpoints –
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q4 2020 Results - Earnings Call Transcript
01:43pm, Thursday, 04'th Mar 2021
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q4 2020 Results - Earnings Call Transcript
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
09:08am, Thursday, 04'th Mar 2021
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.33% and 153.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
07:01am, Thursday, 04'th Mar 2021
– Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 –
Fulcrum Therapeutics Announces CEO Transition
07:00am, Thursday, 04'th Mar 2021
– Robert J. Gould, Ph.D. announces retirement; will continue to serve as board member and advisor –
Fulcrum Therapeutics Recognizes Rare Disease Day 2021
07:00am, Friday, 26'th Feb 2021
Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world Theme of global unity highlights critical role of
CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
10:34pm, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
04:00pm, Tuesday, 19'th Jan 2021
Owen Wallace to Transition to Scientific Advisory Board Owen Wallace to Transition to Scientific Advisory Board
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
07:00am, Wednesday, 09'th Dec 2020
Event will review the company's novel approach to inducing fetal hemoglobin
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
07:30am, Friday, 13'th Nov 2020
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call Transcript
12:45pm, Tuesday, 10'th Nov 2020
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call Transcript
Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
04:01pm, Wednesday, 04'th Nov 2020
Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058 Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058
